CD274 and non-small cell lung carcinoma: Furthermore, using a BMI cutoff value of 21.4 kg/m2, BMI independently predicted survival because patients with high BMIs (≥21.4 kg/m2) had significantly longer OS (not reached vs. 14.1 months, p = 0.006) than patients with low BMIs (<21.4 kg/m2) and among patients with NSCLC and high PD‐L1 expression (≥50%) who were administered first‐line pembrolizumab monotherapy.9